Boothwyn Pharmacy LLC
Has Boothwyn Pharmacy LLC received an FDA warning letter about GLP-1 drugs?
Yes. FDA issued Boothwyn Pharmacy LLC a warning letter naming semaglutide and tirzepatide, dated Jan 16, 2026, with the FDA subject line “Compounding Pharmacy/Adulterated Drug Products.” openFDA also lists 3 drug recall reports for the firm naming semaglutide.
FDA records in this index name Boothwyn Pharmacy LLC from Jul 9, 2025 to Jan 16, 2026.
- Names in FDA records
- Boothwyn Pharmacy LLC; Boothwyn Pharmacy, LLC
- Type named in FDA records
- Compounding pharmacy
- FDA warning letters
- 1
- Drug recall reports
- 3
- Drugs named
- Semaglutide, Tirzepatide
- Latest record
- Jan 16, 2026
FDA warning letters
| Later letters FDA lists | Letter | |||
|---|---|---|---|---|
| Jan 16, 2026 | Compounding Pharmacy/Adulterated Drug Products | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.
FDA’s summary excerpts
- Jan 16, 2026: … differed from their labeled amounts. For example, your Semaglutide 2.5mg/mL Injection was subpotent (lot # 03042025@ … purports or is represented to possess. Accordingly, your Semaglutide 2.5mg/mL Injection and Tirzepatide 10mg/mL … for example your Fluorescein 2 % Ophthalmic Solution, Semaglutide 2.5mg/mL Injection, and Tirzepatide 10mg/mL … Full letter
Drug recalls
| Record | |||||
|---|---|---|---|---|---|
| Jul 9, 2025 | Semaglutide, 2.5 mg/mL injection, 0.8 mL, Boothwyn Pharmacy | Subpotent Drug | Class II | Ongoing | D-0608-2025 |
| Jul 9, 2025 | Semaglutide, 2.5 mg/mL injection, 2 mL., Boothwyn Pharmacy | Subpotent Drug | Class II | Ongoing | D-0606-2025 |
| Jul 9, 2025 | Semaglutide, 2.5 mg/mL injection, 4 mL, Boothwyn Pharmacy | Subpotent Drug | Class II | Ongoing | D-0609-2025 |
FDA compounding inspections and actions
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists one facility under this exact legal name. These entries cover all of the facility’s compounding, not only GLP-1 drugs.
Boothwyn Pharmacy LLC, Kennett Square, PA (503A)
5 listed actions, including 3 Form 483s and 1 warning letter (2021 to 2026).
| Document | |||
|---|---|---|---|
| Jan 16, 2026 | Warning letter | Warning Letter Issued 01/16/2026 | fda.gov |
| Jun 9, 2025 | Form 483 | 483 Issued 06/09/2025 | fda.gov |
| May 13, 2024 | Regulatory meeting | Regulatory Meeting Held 05/13/2024 | Not linked by FDA |
| Sep 12, 2023 | Amended Form 483 | Amended 483 Issued 9/12/2023 | FDA copy (archived) |
| Sep 8, 2021 | Form 483 | 483 Issued 09/08/2021 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.
Pharmacy pages with the same legal name, built from FDA’s 503B list and compounding inspections and actions page: Boothwyn Pharmacy LLC, Kennett Square, PA.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA warning letter, Jan 16, 2026
- openFDA drug recall enforcement reports
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA warning letters (fda.gov full-text search)
Records last pulled Nov 15, 2026. Every entry links to the original public record.